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the three arms: gastrointestinal g3-4 in 7 (1%) cycles, asthenia g3 in 
18 (4%) cycles, neurological g3 in 8 (2%) cycles and skin toxicity g3 
in 3 (<1%) cycles. Response rate as assessed after three cycles and at 
the end of treatment was: arm A=22%/24%, arm B=23%/12%, arm 
C=33%/28%. As March 2007, 129 patients died (44 arm A, 50 arm B 
and 35 arm C). The median survival is 10.7 mo, 8.9 mo and 14.6 mo in 
the arm A, B and C, respectively; HR: B vs A 1.17 (95% CI 0.77-1.78), 
C vs A 0.65 (95% CI0.77-1.78).The 1-yr progression free survival rate 
is:arm A 18%, arm B 8% and arm C 23%. 
Conclusion: All the arms are characterized by a mild toxicity, with 
a worse proﬁle for arm B. Even in the absence of a statistical signiﬁ-
cance, there is a trend of better efﬁcacy of the arm C versus A and 
B, which conﬁrm the role of platinum-based therapy in treatment of 
NSCLC.
P2-292 NSCLC: Cytotoxic Chemotherapy Posters, Tue, Sept 4  
A randomized Phase 3 trial of gemcitabine with or without 
carboplatin in performance status 2 (PS2) patients with advanced 
(stage IIIB with pleural effusion or IV) non-small-cell lung cancer 
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Background: The optimal treatment of patients with advanced NSCLC 
and PS2 has not been resolved. A retrospective analysis of 99 patients 
with PS2 in CALGB 9730 (Lilenbaum, JCO 2005) demonstrated im-
proved survival associated with combination carboplatin-paclitaxel ver-
sus paclitaxel alone (median overall survival=4.7 vs. 2.4 mos., p=.019). 
Gemcitabine-carboplatin (GC) is an active doublet in advanced NSCLC 
and is at least as active as paclitaxel-carboplatin (PC) in PS2 patients 
(ECOG 1599, Tester ASCO 2004). A prospective validation of the 
activity of GC is needed, which is addressed by comparing GC versus 
gemcitabine (G) alone in this setting.
Methods: 161 chemonaïve patients with advanced NSCLC and PS2 
were randomly assigned to G 1250 mg/m2 alone on Days 1 and 8 or GC 
(G 1000 mg/m2 Days 1 and 8 followed by C AUC=5 on Day 1). Cycles 
were repeated every 21 days for 6 cycles or until disease progression or 
intolerable toxicity. The primary endpoint was median survival.
Characteristics/Results G alone GC combination
N enrolled 81 80
Median age (range) 75 (45-89) 73 (46-88)
Male:Female 57:43 54:46
N receiving drug 72 69
Mean cycles (range) 3.3 (1-6) 4.0 (1-6)
Relative dose intensity, % G:C 91:NA 72:90
G3 and 4 neutropenia, % pts G3:4 2.8:1.4 15.9:11.6
G3 and 4 thrombocytopenia, % pts G3:4 0:0 8.7:10.1
G3 and 4 febrile neutropenia, % pts G3:4 0:0 0:0
G3 and 4 anemia, % pts G3:4 1.4:0 7.2:0
N assessed for response 70 67
CR, % O O
PR, % 7.1 31.3
SD, % 35.7 31.3
PD, % 17.1 14.9
Unknown response, % 40.0 22.4
FACT-L trial outcome index (mean) 
Baseline 49.4 50.6
Cycle 1 49.27 50.15
Cycle 2 51.92 54.09
Cycle 3 51.08 55.27
Cycle 4 51.09 57.43
Cycle 5 50.11 59.53
Median survival following randomization (mos) 5.22 6.97
95% CI 3.61, 7.92 4.53, 10.81
Events:censored 45:24 44:23
Log-rank P value 0.489  
Median PFS following randomization (mos) 2.79 4.01
95% CI 1.84, 4.14 2.63, 6.14
Events:censored 52:17 48:19
Log-rank P value 0.424  
Cox regression model of survival Hazard ratio P value
GC vs G 0.84 0.415
Baseline LDH 1.70 0.017
Baseline weight 1.50 0.057
Conclusions: GC resulted in an improved response rate, overall 
survival, and progression-free survival time, but differences were not 
statistically signiﬁcant. As expected, G3-4 toxicities were greater with 
GC. Patients receiving GC had improved FACT-L quality-of-life scores 
at each cycle of treatment. Elevated baseline LDH and weight were 
associated with worsened outcome.
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Background: Pemetrexed (P), a multi-targeted antifolate, was syner-
gisitic with gemcitabine (G) in preclinical models. A Phase 1/2 trial was 
conducted to determine the optimal dose and sequence of the drugs and 
their effect on pts with advanced NSCLC.
Methods: In Phase 1, pts with advanced solid tumors were enrolled. 
In Phase 2, pts had Stage IIIB (with pleural effusion) or IV NSCLC, 
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ECOG PS of 0 or 1, no prior systemic therapy. In both Phases, G was 
followed immediately by P on Day 1 every 14 days. Cycles were 
repeated for 12 treatments or until disease progression. All pts received 
folic acid, Vitamin B12 and steroid prophylaxis.
Results: Phase I dose-escalation resulted in a recommended Phase 2 
dose of G 1500 mg/m2 followed by P 500mg/m2. DLTs at this level 
were G3 diarrhea, hypotension, and atrial ﬁbrillation. 53 pts (29 male, 
24 female) were enrolled in Phase 2: median age = 64 (range: 35, 80), 
ECOG performance status 0:1 = 38%:60%, Stage IIIB:IV = 19%:81%. 
312 cycles of treatment were administered and 14 patients had dose 
reductions (26.4%); median number of doses was 5 for both G and P, 
and median dose intensity was 98.05% for both G and P. Conﬁrmed 
responses were 0 CRs, 11 PRs, (20.8%), 23 SDs (43.4%), and 14 PDs 
(26.4%), with a median duration of response of 10.3 mos (95%CI, 3.2, 
20.0). Patient-based G3/4 hematologic events included febrile neu-
tropenia (9.4%), neutropenia (28.3%), and thrombocytopenia (5.7%). 
Grade 3/4 nonhematologic events included fatigue (22.6%), dyspnea 
(7.5%), dehydration (7.5%), diarrhea (5.7%), constipation (3.8%), nau-
sea (3.8%), ALT elevation (3.8%), and pneumonia (1.9%). Median TTP 
was 4.6 mos (95%CI, 2.8, 6.2; 30.2% censored) and median OS was 
10.1 mos (95%CI, 6.0, 14.1; 41.0% 1-yr survival; 20.8% censored).
Conclusion: Biweekly G and P appear to be well tolerated in advanced 
NSCLC. A median OS of 10.1 mos and clinical beneﬁt rate (ORR + 
SD) of 64.2% indicates activity in patients with advanced NSCLC. The 
dose intensity for biweekly G and P is higher than a previously reported 
6-cycle, 21-day regimen with median dose intensity of 83.2% for P and 
82.2% for G (West, et al. Proc ASCO 2005; 7117).
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Background: We conducted retrospective study to evaluate efﬁcacy 
and tolerability to single-agent TS-1 which is a newly developed oral 
ﬂuoropyrimidine anti-tumor agent chemotherapy in advanced non-
small cell lung cancer patients who received two or three standard or 
approval chemotherapy regimens including platinum and docetaxel 
and/or EGFR-TKIs in clinical practice. 
Methods: Sixty three patients treated single agent TS-1 chemotherapy 
for advanced NSCLC between January 2005 and November 2006 at 
the Shizuoka Cancer Center and 35 patients were fulﬁlled criteria. The 
treatment schedule comprised an oral administration of TS-1 at 120mg 
/ day, one cycle of TS-1 consisted of consecutive administration for 28 
days followed by a 14 days rest.
Results: All 35 patients were evaluable for survival, response and 
toxicity. Patients proﬁles were; M/F 27/8, median age 63 (range:42-77), 
PS 0/1/2 18/14/3, adeno/ non-adeno 24/11 number of prior chemother-
apy 2/3/>4 4/14/17. All adeno patients had been administered EGFR-
TKIs. Median number of delivered cycle is two cycles (range 1-9). Of 
these 35 patients, 2 (5.7%) experienced partial response, 12 (34.2%) 
stable disease. The median survival time and time to progression 
after initiation of oral TS-1 administration was 208 days and 43 days, 
respectively. 1-year survival rate was 37.8%. Toxicities were mild as 
follows: G 3/4 neutropenia 3%, G 3/4 anemia 6%, G 3/4 diarrhea 6%, 
G 3/4 nausea/vomiting, anorexia, fatigue, stomatitis, 3%, respectively. 
As unexpected toxicity, G3 pneumonitis occurred in one patient. 
Conclusions: Single-agent TS-1 chemotherapy has modest activity in 
patients with NSCLC after failed platinum and docetaxel and/or EGFR-
TKI chemotherapy. 
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Platinum-based chemotherapy has been proved effective in patients 
with advanced non-small cell lung cancer (NSCLC). Among these 
regimens, the combination of carboplatin and gemcitabine is one of the 
most active against NSCLC. However, the optimal administration regi-
men has not yet been determined. This study aims to evaluate response 
rates with gemcitabine as a 120-minutes’ perfusion versus a 30-min-
utes’ perfusion, both combined with carboplatin.
Randomized, prospective, multicenter, phase II study. Patients with 
stage IIIB or IV, ECOG performance status 0-1, who had not had prior 
chemotherapy, were assigned to receive gemcitabine 1200 mg/m2 iv, 
10mg/m2/min (arm A) or 30 minutes perfusion (arm B) (days 1 and 8) 
plus carboplatin AUC 5 iv in continuous perfusion (day 1). The cycles’ 
duration was 21 days and 6 cycles were foreseen.
Ninety seven patients were enrolled (48 in arm A and 49 in arm B), 
76.0% men, mean age 63.8±9.1 years (46-87 range), 45.4% smokers.
The most frequent NSCLC histological subtypes were adenocarci-
noma (52.6%) and epidermoid carcinoma (29.7%). Diagnostic was 
histological in 63.2% of the patients, cytological in 32.6% and both 
in 4.2%. Nineteen patients had stage IIIB (19.6%) and 78 stage IV 
(80.4%); ECOG performance status 0 in 7.4% of the patients and 1 in 
92.6%. Pre-treatment cancer metastases were found in lungs (56.4%), 
liver (25.6%), bone (25.6%), suprarenal (17.9%) and lymphatic nodes 
(5.1%). A total of 413 chemotherapy cycles were administered with a 
median of 4 cycles (range 2-6).
After 6 cycles, 24 patients died (11 in arm A and 13 in arm B); 10 
deaths were not considered as disease progression. 
Response rate was evaluated in 87 patients (39 in arm A and 48 in arm 
B). No patient achieved complete response. Partial response was 17.9% 
vs. 18.8%; stable disease rate was 15.4% and 14.6% and progression 
disease rate was 33.3% and 45.8%, arm A and B, respectively. Thirteen 
patients from arm A and 10 from B survived, however their response to 
treatment was not yet evaluated. There were no signiﬁcant differences 
between groups.
Thirteen percent of the patients discontinued treatment due to toxicity. 
Twelve adverse events were considered serious.
According to the WHO toxicity scale, 26.8% of the patients had grade 
3-4 neutropenia and 8.2% had grade 3-4 thrombocytopenia. The other 
